|
Favorable
|
t(8;21)(q22;q22.1); RUNX1-RUNX1T1
|
|
inv (16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
|
|
Mutated NPM1 without FLT3-ITD
|
|
Mutated NPM1 with FLT3-ITDlow
|
|
Biallelic mutated CEBPA
|
|
Intermediate
|
Mutated NPM1 and FLT3-ITDhigh
|
|
Wild-type NPM1 without FLT3-ITD
|
|
Wild-type NPM1 with FLT3-ITDlow
|
|
t(9;11)(p21.3;q23.3); MLLT3-KMT2A
|
|
Cytogenetic abnormalities not classified
|
|
Adverse
|
t(6;9)(p23;q34.1); DEK-NUP214
|
|
t(v;11q23.3); KMT2A rearranged
|
|
t(9;22)(q34.1;q11.2); BCR-ABL1
|
|
inv (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)
|
|
Complex karyotype, monosomal karyotype
|
|
-5 or del(5q); −7; −17/abn(17p)
|
|
Wild-type NPM1 and FLT3-ITDhigh
|
|
Mutated RUNX1
|
|
Mutated ASXL1
|
|
Mutated TP53
|
